Navigation Links
DNA2.0 Patents New DNA Cloning Method
Date:12/14/2012

Menlo Park, CA (PRWEB) December 13, 2012

DNA2.0, the leading bioengineering solutions provider, today announced that it has been awarded US patent 8,323,930 for a new cloning method that facilitates high-throughput manufacturing of synthetic DNA. The company’s new technology for one-step DNA cloning is based on the DNA topoisomerase enzyme and its capacity to nick and reanneal DNA. Because the process does not rely on PCR, DNA2.0’s method ensures no introduced sequence errors in the cloned version of the newly manufactured synthetic gene.

“Industrializing the production of synthetic genes requires more than simply increasing the capacity and accuracy of oligonucleotide synthesis. Accordingly, DNA2.0 has developed a new method to efficiently and consistently clone assembled oligonucleotides to generate clonal entities in a one-step process,” said Jeremy Minshull, CEO and cofounder of DNA2.0. “DNA2.0 is proud to be an innovation leader so that our customers can focus on their research rather than reinventing the wheel. We are excited to add this patent to our growing portfolio of technological achievements in synthetic biology.”

About DNA2.0
DNA2.0 is the leading bioengineering solutions provider. Founded in 2003, DNA2.0 offers an integrated pipeline of solutions for the research community, including gene design, optimization, synthesis, and cloning, as well as platforms for protein and strain engineering. It is the fastest provider of synthetic genes—based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 is by far the most published synthetic gene vendor, providing expert support to and collaboration with scientists. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene design and synthesis processes and new protein optimization technologies. DNA2.0’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif. For more information, please visit http://www.DNA20.com.

Read the full story at http://www.prweb.com/releases/2012/12/prweb10234599.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. DNA2.0 Patents Key Method for Synthesizing Bioplastic Polymer
2. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
3. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
4. ERT Granted Patents on Clinical Trial Participant Compliance
5. Olympus Licenses Digital Pathology Patents to Zeiss
6. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
7. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
8. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
9. Cloning could make structurally pure nanotubes for nanoelectronics
10. Rigaku Publishes New Application Note: Cement Raw Meal Analysis by Pressed Powder Method on the ZSX Primus III+
11. Sequenom, Inc. Announces Issuance Of Patent For Methods Of Detecting Fetal Aneuploidy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
Breaking Biology News(10 mins):